Transgene SA
Update in progressTNG.PA (Paris)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Transgene SA is a France-based biotechnology company that develops therapeutic vaccines and oncolytic viruses for cancer. Its programs include TG4050 for ovarian and head and neck cancers (Phase II), TG4001 for HPV-16–positive cancers (Phase II), TG6002 and BT-001 oncolytic viruses (Phase I/II), and TG6050 for non-small cell lung cancer (Phase I). Pexa-Vec is another oncolytic candidate. The company partners with multiple pharma groups and was founded in 1979, based in Illkirch-Graffenstaden.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketParis (PAR)
- LocationFrance
- CEODr. Alessandro Riva M.D.
- Founded1979
- Employees145
- Websitewww.transgene.com
Identifiers
- ISINFR0005175080